Participants attended an informed consent, medical history and treatment initiation visit (V1, week 0), several intermediate visits depending on the local clinical practice (V2.X, weeks 133) and an EOS visit (V3, weeks 3444) to assess efficacy and safety parameters, and PROs
We therefore measured G protein-dependent cAMP generation and -arrestin-1 and -2 recruitment with exendin-4, exendin-phe1, and exendin-asp3 at two time-points to avoid kinetic artefacts 38 , and calculated the pathway bias by fitting the response data to a modified form of the operational model of agonism 39 (Fig
Risk reduction strategies may include postponement/cancellation of the procedure, ingestion of a clear fluid diet for some period of time before the nothing by mouth period, avoidance of deep sedation/general anesthesia if possible, and use of rapid-sequence induction if general anesthesia is required
Just won't work as well
Each round of treatment lasts 23 days
SURMOUNT-5 Trial Overview SURMOUNT-5 (NCT05822830) is a multicenter, randomized, open-label Phase 3b trial aimed at assessing the efficacy and safety of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adults with obesity or overweight, with at least one comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or cardiovascular disease), and no diabetes
